{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:09:06Z","timestamp":1786982946275,"version":"build-2736575974"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s41669-024-00540-4","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T13:58:51Z","timestamp":1731679131000},"page":"179-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Economic Burden of Haemophilia from a Societal Perspective: A Scoping Review"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3713-237X","authenticated-orcid":false,"given":"Amr A.","family":"El-Sayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy S.","family":"Bolous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"540_CR1","unstructured":"World Federation of Hemophilia. Report on the Annual Global Survey 2022. Montr\u00e9al, 2023. [Online]. https:\/\/www1.wfh.org\/publications\/files\/pdf-2399.pdf"},{"issue":"1","key":"540_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","volume":"7","author":"E Berntorp","year":"2021","unstructured":"Berntorp E, et al. Haemophilia. Nat Rev Dis Prim. 2021;7(1):45.","journal-title":"Nat Rev Dis Prim"},{"key":"540_CR3","unstructured":"Mehta P, Reddivari AKR (2024) Hemophilia. [Updated 2023 Jun 5]. In: StatPearls [Internet], Treasure Island (FL): StatPearls Publishing; 2024 Jan. [Online]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551607\/"},{"key":"540_CR4","doi-asserted-by":"publisher","first-page":"46958019845280","DOI":"10.1177\/0046958019845280","volume":"56","author":"KAR Kadhim","year":"2019","unstructured":"Kadhim KAR, Al-Lami FH, Baldawi KH. Epidemiological profile of hemophilia in Baghdad-Iraq. Inquiry. 2019;56:46958019845280. https:\/\/doi.org\/10.1177\/0046958019845280.","journal-title":"Inquiry"},{"issue":"9","key":"540_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/17474086.2022.2110063","volume":"15","author":"EC Rodriguez-Merchan","year":"2022","unstructured":"Rodriguez-Merchan EC. Past, present, and future of orthopedic surgery in hemophilia: looking to a world without bleeding and arthropathy in the near future. Expert Rev Hematol. 2022;15(9):821\u201331.","journal-title":"Expert Rev Hematol"},{"key":"540_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020;26:1\u2013158. https:\/\/doi.org\/10.1111\/hae.14046.","journal-title":"Haemophilia"},{"issue":"6","key":"540_CR7","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/hae.14412","volume":"27","author":"ME Mancuso","year":"2021","unstructured":"Mancuso ME, et al. Prophylaxis in children with haemophilia in an evolving treatment landscape. Haemophilia. 2021;27(6):889\u201396.","journal-title":"Haemophilia"},{"issue":"2","key":"540_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/pathogens12020318","volume":"12","author":"A Farrugia","year":"2023","unstructured":"Farrugia A. The evolution of the safety of plasma products from pathogen transmission\u2014a continuing narrative. Pathogens. 2023;12(2):318.","journal-title":"Pathogens"},{"issue":"4","key":"540_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2450\/2010.0067-10","volume":"8","author":"M Franchini","year":"2010","unstructured":"Franchini M. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus. 2010;8(4):292\u20136. https:\/\/doi.org\/10.2450\/2010.0067-10.","journal-title":"Blood Transfus"},{"key":"540_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/9781119719809.ch37","volume-title":"Rossi\u2019s principles of transfusion medicine","author":"GM Woods","year":"2022","unstructured":"Woods GM, Sidonio RF Jr. Coagulation concentrates for inherited bleeding disorders. In: Rossi\u2019s principles of transfusion medicine. New York: Wiley; 2022. p. 424\u201342. https:\/\/doi.org\/10.1002\/9781119719809.ch37."},{"key":"540_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.thromres.2019.12.012","volume":"196","author":"P Chowdary","year":"2020","unstructured":"Chowdary P. Extended half-life recombinant products in haemophilia clinical practice\u2014expectations, opportunities and challenges. Thromb Res. 2020;196:609\u201317. https:\/\/doi.org\/10.1016\/j.thromres.2019.12.012.","journal-title":"Thromb Res"},{"issue":"3","key":"540_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4274\/tjh.galenos.2019.2018.0393","volume":"36","author":"MC Ar","year":"2019","unstructured":"Ar MC, Balkan C, Kavakl\u0131 K. Extended half-life coagulation factors: a new era in the management of hemophilia patients. Turk J Haematol Off J Turk Soc Haematol. 2019;36(3):141\u201354. https:\/\/doi.org\/10.4274\/tjh.galenos.2019.2018.0393.","journal-title":"Turk J Haematol Off J Turk Soc Haematol."},{"key":"540_CR13","first-page":"221","volume":"15","author":"E Marchesini","year":"2021","unstructured":"Marchesini E, Morfini M, Valentino L. Recent advances in the treatment of hemophilia: a review. Biol Targ Ther. 2021;15:221\u201335.","journal-title":"Biol Targ Ther"},{"issue":"1","key":"540_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/hematology.2021000253","volume":"2021","author":"P Ellsworth","year":"2021","unstructured":"Ellsworth P, Ma A. Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? Hematology. 2021;2021(1):219\u201325.","journal-title":"Hematology"},{"issue":"5","key":"540_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40259-023-00615-4","volume":"37","author":"CD Thornburg","year":"2023","unstructured":"Thornburg CD, Simmons DH, von Drygalski A. Evaluating gene therapy as a potential paradigm shift in treating severe hemophilia. BioDrugs. 2023;37(5):595\u2013606. https:\/\/doi.org\/10.1007\/s40259-023-00615-4.","journal-title":"BioDrugs"},{"issue":"6","key":"540_CR16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/vox.13263","volume":"117","author":"T Burnouf","year":"2022","unstructured":"Burnouf T, Epstein J, Faber J, Smid M. Stepwise access to safe plasma proteins in resource-constrained countries: Local production and pathways to fractionation\u2014REPORT of an International Society of Blood Transfusion Workshop. Vox Sang. 2022;117(6):789\u201395.","journal-title":"Vox Sang"},{"issue":"9","key":"540_CR17","doi-asserted-by":"publisher","first-page":"e689","DOI":"10.1016\/S2352-3026(22)00209-5","volume":"9","author":"GF Pierce","year":"2022","unstructured":"Pierce GF, et al. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Lancet Haematol. 2022;9(9):e689\u201397.","journal-title":"Lancet Haematol."},{"key":"540_CR18","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/hae.14785","volume":"29","author":"S Bansal","year":"2023","unstructured":"Bansal S, et al. Low dose emicizumab prophylaxis in haemophilia a patients: a pilot study from India. Haemoph Off J World Fed Hemoph. 2023;29:931.","journal-title":"Haemoph Off J World Fed Hemoph"},{"issue":"4","key":"540_CR19","first-page":"841","volume":"13","author":"DT Drisya","year":"2023","unstructured":"Drisya DT, Meenu P, Usha KC. Seroprevalence of hepatitis B, hepatitis C, and human immunodeficiency virus in hemophilia A patients: a descriptive study. Natl J Physiol Pharm Pharmacol. 2023;13(4):841\u20134.","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"540_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/JBM.S291536","volume":"14","author":"A Ndoumba-Mintya","year":"2023","unstructured":"Ndoumba-Mintya A, Diallo YL, Tayou TC, Mbanya DN. Optimizing haemophilia care in resource-limited countries: current challenges and future prospects. J Blood Med. 2023;14:141\u20136. https:\/\/doi.org\/10.2147\/JBM.S291536.","journal-title":"J Blood Med"},{"issue":"1","key":"540_CR21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/hae.14682","volume":"29","author":"A Tlacuilo-Parra","year":"2023","unstructured":"Tlacuilo-Parra A, Soto-Padilla J, Toro-Castro L, Gutierrez-Hermosillo V, Guevara-Gutierrez E. Diminished cortical bone density of long bones among children with haemophilic arthropathy. Haemophilia. 2023;29(1):274\u201381.","journal-title":"Haemophilia"},{"key":"540_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-3-319-67144-4","volume-title":"Rare diseases epidemiology: update and overview, ch. 17","author":"R Linertov\u00e1","year":"2017","unstructured":"Linertov\u00e1 R, Garc\u00eda-P\u00e9rez L, Gorostiza I. Cost-of-illness in rare diseases. In: de la Paz MP, Taruscio D, Groft SC, editors. Rare diseases epidemiology: update and overview, ch. 17. 2nd ed. Cham: Springer; 2017. p. 283\u201397. https:\/\/doi.org\/10.1007\/978-3-319-67144-4.","edition":"2"},{"issue":"Suppl 1","key":"540_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1355-0691.2004.00879.x","volume":"10","author":"M Carcao","year":"2004","unstructured":"Carcao M, Ungar WJ, Feldman BM. Cost-utility analysis in evaluating prophylaxis in haemophilia. Haemophilia. 2004;10(Suppl 1):50\u20137. https:\/\/doi.org\/10.1111\/j.1355-0691.2004.00879.x.","journal-title":"Haemophilia"},{"key":"540_CR24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/9781118398258","volume-title":"Textbook of hemophilia, ch. 65","author":"KS Carlsson","year":"2014","unstructured":"Carlsson KS, Berntorp EE. The economics of hemophilia treatment. In: Lee CA, Berntorp EE, Hoots WK, editors. Textbook of hemophilia, ch. 65. 3rd ed. Chichester: Wiley Online Library; 2014. p. 489\u201394. https:\/\/doi.org\/10.1002\/9781118398258.","edition":"3"},{"key":"540_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/9781119979401","volume-title":"The economics of prophylaxis: does prophylaxis with clotting factor represent value for money?","author":"A Miners","year":"2011","unstructured":"Miners A. The economics of prophylaxis: does prophylaxis with clotting factor represent value for money? Chichester: Wiley; 2011. https:\/\/doi.org\/10.1002\/9781119979401."},{"issue":"3","key":"540_CR26","first-page":"141","volume":"13","author":"MDJ Peters","year":"2015","unstructured":"Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. JBI Evid Implement. 2015;13(3):141\u20136.","journal-title":"JBI Evid. Implement."},{"key":"540_CR27","first-page":"406","volume-title":"JBI manual for evidence synthesis, ch. 11","author":"M Peters","year":"2020","unstructured":"Peters M, Godfrey C, McInerney P, Munn Z, Tricco A, Khalil H. Scoping reviews. In: Aromataris E, Munn Z, editors. JBI manual for evidence synthesis, ch. 11. Adelaide: Joanna Briggs Institute; 2020. p. 406\u201351."},{"issue":"7","key":"540_CR28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/m18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/m18-0850.","journal-title":"Ann Intern Med"},{"issue":"Suppl 7","key":"540_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/ejh.12499","volume":"94","author":"MR Baghaipour","year":"2015","unstructured":"Baghaipour MR, SteenCarlsson K. Strategies for inhibitor treatment and costs in the short and long term: a critical evaluation of recent clinical studies. Eur J Haematol. 2015;94(Suppl 7):30\u20137. https:\/\/doi.org\/10.1111\/ejh.12499.","journal-title":"Eur J Haematol"},{"issue":"3","key":"540_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40273-017-0588-z","volume":"36","author":"PA Cortesi","year":"2018","unstructured":"Cortesi PA, D\u2019Angiolella LS, Lafranconi A, Micale M, Cesana G, Mantovani LG. Modern treatments of haemophilia: review of cost-effectiveness analyses and future directions. Pharmacoeconomics. 2018;36(3):263\u201384. https:\/\/doi.org\/10.1007\/s40273-017-0588-z.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"540_CR31","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/ejh.13108","volume":"101","author":"LS D\u2019Angiolella","year":"2018","unstructured":"D\u2019Angiolella LS, et al. The socioeconomic burden of patients affected by hemophilia with inhibitors. Eur J Haematol. 2018;101(4):435\u201356. https:\/\/doi.org\/10.1111\/ejh.13108.","journal-title":"Eur J Haematol"},{"issue":"2","key":"540_CR32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/hae.12009","volume":"19","author":"AH Miners","year":"2013","unstructured":"Miners AH. Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much? Haemophilia. 2013;19(2):174\u201380. https:\/\/doi.org\/10.1111\/hae.12009.","journal-title":"Haemophilia"},{"issue":"8","key":"540_CR33","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1517\/14656566.8.8.1127","volume":"8","author":"JM Stephens","year":"2007","unstructured":"Stephens JM, Joshi AV, Sumner M, Botteman MF. Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors. Expert Opin Pharmacother. 2007;8(8):1127\u201336. https:\/\/doi.org\/10.1517\/14656566.8.8.1127.","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"540_CR34","doi-asserted-by":"publisher","first-page":"632","DOI":"10.18553\/jmcp.2018.24.7.632","volume":"24","author":"T Thorat","year":"2018","unstructured":"Thorat T, Neumann PJ, Chambers JD. Hemophilia burden of disease: a systematic review of the cost-utility literature for hemophilia. J Manag Care Spec Pharm. 2018;24(7):632\u201342. https:\/\/doi.org\/10.18553\/jmcp.2018.24.7.632.","journal-title":"J Manag Care Spec Pharm"},{"key":"540_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/596164","volume":"2015","author":"B Unim","year":"2015","unstructured":"Unim B, Veneziano MA, Boccia A, Ricciardi W, La Torre G. Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demand. Sci World J. 2015;2015: 596164. https:\/\/doi.org\/10.1155\/2015\/596164.","journal-title":"Sci World J"},{"issue":"10","key":"540_CR36","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/pbc.25543","volume":"62","author":"M Valente","year":"2015","unstructured":"Valente M, et al. Health economic models in hemophilia A and utility assumptions from a clinician\u2019s perspective. Pediatr Blood Cancer. 2015;62(10):1826\u201331. https:\/\/doi.org\/10.1002\/pbc.25543.","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"540_CR37","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.healthpol.2014.12.016","volume":"119","author":"A Angelis","year":"2015","unstructured":"Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119(7):964\u201379. https:\/\/doi.org\/10.1016\/j.healthpol.2014.12.016.","journal-title":"Health Policy"},{"issue":"3","key":"540_CR38","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3390\/ijerph18031101","volume":"18","author":"P Armeni","year":"2021","unstructured":"Armeni P, Cavazza M, Xoxi E, Taruscio D, Kodra Y. Reflections on the importance of cost of illness analysis in rare diseases: a proposal. Int J Environ Res Public Health. 2021;18(3):1101.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"540_CR39","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13023-021-01815-3","volume":"16","author":"L Garc\u00eda-P\u00e9rez","year":"2021","unstructured":"Garc\u00eda-P\u00e9rez L, Linertov\u00e1 R, Valc\u00e1rcel-Nazco C, Posada M, Gorostiza I, Serrano-Aguilar P. Cost-of-illness studies in rare diseases: a scoping review. Orphanet J Rare Dis. 2021;16(1):178. https:\/\/doi.org\/10.1186\/s13023-021-01815-3.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"540_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.hlpt.2021.02.002","volume":"10","author":"AR Sequeira","year":"2021","unstructured":"Sequeira AR, Mentzakis E, Archangelidi O, Paolucci F. The economic and health impact of rare diseases: a meta-analysis. Heal Policy Technol. 2021;10(1):32\u201344.","journal-title":"Heal Policy Technol"},{"key":"540_CR41","doi-asserted-by":"publisher","DOI":"10.1596\/978-1-4648-1530-0","volume-title":"Purchasing power parities and the size of world economies: results from the 2017 International Comparison Program","author":"The World Bank","year":"2020","unstructured":"The World Bank. Purchasing power parities and the size of world economies: results from the 2017 International Comparison Program. Washington, DC: The World Bank; 2020. https:\/\/doi.org\/10.1596\/978-1-4648-1530-0."},{"key":"540_CR42","unstructured":"The World Bank. Fundamentals of purchasing power parities. [Online]. https:\/\/thedocs.worldbank.org\/en\/doc\/332341517441011666-0050022018\/original\/PPPbrochure2017webformatrev.pdf. Accessed 26 Sep 2023."},{"issue":"9","key":"540_CR43","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jval.2019.03.021","volume":"22","author":"HC Turner","year":"2019","unstructured":"Turner HC, Lauer JA, Tran BX, Teerawattananon Y, Jit M. Adjusting for inflation and currency changes within health economic studies. Value Heal. 2019;22(9):1026\u201332.","journal-title":"Value Heal."},{"key":"540_CR44","unstructured":"The World Bank. PPP conversion factor, GDP (LCU per international $). [Online]. https:\/\/data.worldbank.org\/indicator\/PA.NUS.PPP. Accessed 26 Sep 2023."},{"key":"540_CR45","doi-asserted-by":"crossref","unstructured":"Ha J, Kose MA, Ohnsorge F. One-stop source: a global database of inflation. World Bank, Washington (DC), Policy Research Working Paper; No. 9737, 2021. [Online]. https:\/\/www.worldbank.org\/en\/research\/brief\/inflation-database","DOI":"10.1596\/1813-9450-9737"},{"key":"540_CR46","unstructured":"The World Bank. Official exchange rate (LCU per US$, period average). [Online]. https:\/\/data.worldbank.org\/indicator\/PA.NUS.FCRF. Accessed 4 Sep 2023."},{"issue":"5","key":"540_CR47","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1055\/s-0037-1615097","volume":"79","author":"RL Bohn","year":"1998","unstructured":"Bohn RL, Avorn J, Glynn RJ, Choodnovskiy I, Haschemeyer R, Aledort LM. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost. 1998;79(5):932\u20137.","journal-title":"Thromb Haemost"},{"issue":"5","key":"540_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.anr.2019.11.002","volume":"13","author":"C Lockwood","year":"2019","unstructured":"Lockwood C, dos Santos KB, Pap R. Practical guidance for knowledge synthesis: scoping review methods. Asian Nurs Res (Korean Soc Nurs Sci). 2019;13(5):287\u201394. https:\/\/doi.org\/10.1016\/j.anr.2019.11.002.","journal-title":"Asian Nurs Res (Korean Soc Nurs Sci)"},{"key":"540_CR49","unstructured":"The World Bank. Low and middle income. Online. [Online]. https:\/\/data.worldbank.org\/income-level\/low-and-middle-income"},{"issue":"1","key":"540_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1365-2257.1979.tb00586.x","volume":"1","author":"GI Ingram","year":"1979","unstructured":"Ingram GI, et al. Home treatment in haemophilia: clinical, social and economic advantages. Clin Lab Haematol. 1979;1(1):13\u201327. https:\/\/doi.org\/10.1111\/j.1365-2257.1979.tb00586.x.","journal-title":"Clin Lab Haematol"},{"key":"540_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14766","author":"P Chowdary","year":"2023","unstructured":"Chowdary P, et al. The humanistic and economic burden of problem joints for children and adults with moderate or severe haemophilia A: analysis of the CHESS population studies. Haemophilia. 2023. https:\/\/doi.org\/10.1111\/hae.14766.","journal-title":"Haemophilia"},{"issue":"4","key":"540_CR52","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1365-2516.1996.tb00139.x","volume":"2","author":"TD Szucs","year":"1996","unstructured":"Szucs TD, \u00d6ffner A, Schramm W. Socioeconomic impact of haemophilia care: results of a pilot study. Haemophilia. 1996;2(4):211\u20137.","journal-title":"Haemophilia"},{"issue":"1","key":"540_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1046\/j.1365-2516.2002.00580.x","volume":"8","author":"W Schramm","year":"2002","unstructured":"Schramm W, et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia. 2002;8(1):33\u201343. https:\/\/doi.org\/10.1046\/j.1365-2516.2002.00580.x.","journal-title":"Haemophilia"},{"issue":"3","key":"540_CR54","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4103\/jpgm.JPGM_701_16","volume":"64","author":"U Jadhav","year":"2018","unstructured":"Jadhav U, Mukherjee K. Assessment of healthcare measures, healthcare resource use, and cost of care among severe hemophilia A patients in Mumbai region of India. J Postgrad Med. 2018;64(3):138\u201344. https:\/\/doi.org\/10.4103\/jpgm.JPGM_701_16.","journal-title":"J Postgrad Med"},{"issue":"5","key":"540_CR55","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1365-2516.2004.00952.x","volume":"10","author":"KS Carlsson","year":"2004","unstructured":"Carlsson KS, et al. Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia. 2004;10(5):515\u201326. https:\/\/doi.org\/10.1111\/j.1365-2516.2004.00952.x.","journal-title":"Haemophilia"},{"issue":"3","key":"540_CR56","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1046\/j.1365-2516.2001.00502.x","volume":"7","author":"H Ekert","year":"2001","unstructured":"Ekert H, Brewin T, Boey W, Davey P, Tilden D. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX. Haemophilia. 2001;7(3):279\u201385. https:\/\/doi.org\/10.1046\/j.1365-2516.2001.00502.x.","journal-title":"Haemophilia"},{"issue":"1","key":"540_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-017-0660-y","volume":"12","author":"J O\u2019Hara","year":"2017","unstructured":"O\u2019Hara J, Hughes D, Camp C, Burke T, Carroll L, Diego D-AG. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12(1):1\u20138.","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl. 1","key":"540_CR58","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000214535","volume":"10","author":"K Schimpf","year":"1981","unstructured":"Schimpf K, Niederberger M. Cost effectiveness in treatment of severe hemophilia. Pathophysiol Haemost Thromb. 1981;10(Suppl. 1):185\u20137.","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"1","key":"540_CR59","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1046\/j.1365-2516.2000.00358.x","volume":"6","author":"P Molho","year":"2000","unstructured":"Molho P, et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat.haemophiles@cch.ap-hop-paris.fr. Haemophilia. 2000;6(1):23\u201332. https:\/\/doi.org\/10.1046\/j.1365-2516.2000.00358.x.","journal-title":"Haemophilia"},{"key":"540_CR60","doi-asserted-by":"crossref","unstructured":"Mihailov D, Serban M, Badeti R, Tepeneu P, Schramm W, Lighezan D (2007) Economic evaluation of orthopedic and surgical interventions in hemophiliacs-not only direct medical costs matter. In: 36th Hemophilia Symposium Hamburg 2005. Springer, pp 161\u201316","DOI":"10.1007\/978-3-540-36715-4_30"},{"issue":"Suppl 3","key":"540_CR61","doi-asserted-by":"publisher","first-page":"s567","DOI":"10.2450\/2014.0042-14s","volume":"12","author":"Y Kodra","year":"2014","unstructured":"Kodra Y, et al. The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus. 2014;12(Suppl 3):s567\u201375. https:\/\/doi.org\/10.2450\/2014.0042-14s.","journal-title":"Blood Transfus"},{"issue":"4","key":"540_CR62","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1111\/hae.12715","volume":"21","author":"VE Price","year":"2015","unstructured":"Price VE, Hawes SA, Bouchard A, Vaughan A, Jarock C, Kuhle S. Unmeasured costs of haemophilia: the economic burden on families with children with haemophilia. Haemophilia. 2015;21(4):e294\u20139. https:\/\/doi.org\/10.1111\/hae.12715.","journal-title":"Haemophilia"},{"issue":"6","key":"540_CR63","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3111\/13696998.2015.1016228","volume":"18","author":"Z-Y Zhou","year":"2015","unstructured":"Zhou Z-Y, et al. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. J Med Econ. 2015;18(6):457\u201365. https:\/\/doi.org\/10.3111\/13696998.2015.1016228.","journal-title":"J Med Econ"},{"issue":"8","key":"540_CR64","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jval.2017.04.017","volume":"20","author":"CX Chen","year":"2017","unstructured":"Chen CX, Baker JR, Nichol MB. Economic burden of illness among persons with hemophilia B from HUGS Vb: examining the association of severity and treatment regimens with costs and annual bleed rates. Value Heal. 2017;20(8):1074\u201382.","journal-title":"Value Heal."},{"issue":"3","key":"540_CR65","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/hae.13459","volume":"24","author":"J Koeberlein-Neu","year":"2018","unstructured":"Koeberlein-Neu J, Runkel B, Hilberg T. Cost-utility of a six-month programmed sports therapy (PST) in patients with haemophilia. Haemophilia. 2018;24(3):385\u201394.","journal-title":"Haemophilia"},{"issue":"1","key":"540_CR66","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/16078454.2020.1741205","volume":"25","author":"K Keshavarz","year":"2020","unstructured":"Keshavarz K, Bordbar M, Hashemipoor Z, Jalali FS, Ravangard R. Economic burden of hemophilia A and B: a case in Iran. Hematology. 2020;25(1):149\u201355. https:\/\/doi.org\/10.1080\/16078454.2020.1741205.","journal-title":"Hematology"},{"issue":"1","key":"540_CR67","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13023-021-01774-9","volume":"16","author":"T Burke","year":"2021","unstructured":"Burke T, Asghar S, O\u2019Hara J, Sawyer EK, Li N. Clinical, humanistic, and economic burden of severe hemophilia B in the United States: results from the CHESS US and CHESS US+ population surveys. Orphanet J Rare Dis. 2021;16(1):143. https:\/\/doi.org\/10.1186\/s13023-021-01774-9.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"540_CR68","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1182\/blood-2012-12-470898","volume":"122","author":"K Fischer","year":"2013","unstructured":"Fischer K, et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood. 2013;122(7):1129\u201336. https:\/\/doi.org\/10.1182\/blood-2012-12-470898.","journal-title":"Blood"},{"issue":"Suppl 1","key":"540_CR69","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10198-016-0785-2","volume":"17","author":"M Cavazza","year":"2016","unstructured":"Cavazza M, et al. Social\/economic costs and quality of life in patients with haemophilia in Europe. Eur J Health Econ. 2016;17(Suppl 1):53\u201365. https:\/\/doi.org\/10.1007\/s10198-016-0785-2.","journal-title":"Eur J Health Econ"},{"issue":"02","key":"540_CR70","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1055\/s-0039-1688414","volume":"3","author":"N Gupta","year":"2019","unstructured":"Gupta N, et al. HAEMOcare: the first international epidemiological study measuring burden of hemophilia in developing countries. TH Open. 2019;3(02):e190\u20139.","journal-title":"TH Open"},{"issue":"1","key":"540_CR71","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1186\/s13023-021-02152-1","volume":"16","author":"T Burke","year":"2021","unstructured":"Burke T, Asghar S, O\u2019Hara J, Chuang M, Sawyer EK, Li N. Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe. Orphanet J Rare Dis. 2021;16(1):521. https:\/\/doi.org\/10.1186\/s13023-021-02152-1.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"540_CR72","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13023-022-02301-0","volume":"17","author":"I Rodriguez-Santana","year":"2022","unstructured":"Rodriguez-Santana I, et al. Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study. Orphanet J Rare Dis. 2022;17(1):150. https:\/\/doi.org\/10.1186\/s13023-022-02301-0.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"540_CR73","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13023-022-02300-1","volume":"17","author":"I Rodriguez-Santana","year":"2022","unstructured":"Rodriguez-Santana I, et al. Differential humanistic and economic burden of mild, moderate and severe haemophilia in european adults: a regression analysis of the CHESS II study. Orphanet J Rare Dis. 2022;17(1):148. https:\/\/doi.org\/10.1186\/s13023-022-02300-1.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"540_CR74","first-page":"369","volume":"155","author":"A L\u00f3pez-Facundo","year":"2019","unstructured":"L\u00f3pez-Facundo A, Rodr\u00edguez-Castillejos C, Romero Y, Gay J, Prada D. Impacto econ\u00f3mico de los inhibidores en hemofilia tipo A pedi\u00e1trica. Gac Med Mex. 2019;155(4):369\u201376.","journal-title":"Gac Med Mex"},{"issue":"Suppl 3","key":"540_CR75","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-2516.2010.02257.x","volume":"16","author":"MA Escobar","year":"2010","unstructured":"Escobar MA. Health economics in haemophilia: a review from the clinician\u2019s perspective. Haemophilia. 2010;16(Suppl 3):29\u201334. https:\/\/doi.org\/10.1111\/j.1365-2516.2010.02257.x.","journal-title":"Haemophilia"},{"issue":"4","key":"540_CR76","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3350\/cmh.2014.20.4.327","volume":"20","author":"C Jo","year":"2014","unstructured":"Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327\u201337. https:\/\/doi.org\/10.3350\/cmh.2014.20.4.327.","journal-title":"Clin Mol Hepatol"},{"key":"540_CR77","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/asheducation-2011.1.413","volume":"2011","author":"KA Johnson","year":"2011","unstructured":"Johnson KA, Zhou Z-Y. Costs of care in hemophilia and possible implications of health care reform. Hematol Am Soc Hematol Educ Progr. 2011;2011:413\u20138. https:\/\/doi.org\/10.1182\/asheducation-2011.1.413.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"issue":"1","key":"540_CR78","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40273-015-0325-4","volume":"34","author":"E Onukwugha","year":"2016","unstructured":"Onukwugha E, McRae J, Kravetz A, Varga S, Khairnar R, Mullins CD. Cost-of-illness studies: an updated review of current methods. Pharmacoeconomics. 2016;34(1):43\u201358. https:\/\/doi.org\/10.1007\/s40273-015-0325-4.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"540_CR79","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"key":"540_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.914338","volume":"13","author":"J Delaye","year":"2022","unstructured":"Delaye J, Cacciatore P, Kole A. Valuing the \u2018burden\u2019 and impact of rare diseases: a scoping review. Front Pharmacol. 2022;13: 914338. https:\/\/doi.org\/10.3389\/fphar.2022.914338.","journal-title":"Front Pharmacol"},{"issue":"S6","key":"540_CR81","first-page":"56","volume":"14","author":"JA Siwady","year":"2022","unstructured":"Siwady JA, Molina MD, D\u00edaz LES. An\u00e1lisis de costos del tratamiento a demanda y profil\u00e1ctico de la hemofilia en el Hospital Escuela Universitario, Honduras. Rev Univ y Soc. 2022;14(S6):56\u201365.","journal-title":"Rev Univ y Soc"},{"key":"540_CR82","first-page":"34","volume":"47","author":"VM Chernov","year":"2002","unstructured":"Chernov VM, Lobanova EV, Rumyantsev AG. Estimation of the cost of medical care for children and adolescents with hemophilia. Gematol Transfuziol. 2002;47:34.","journal-title":"Gematol Transfuziol"},{"issue":"14","key":"540_CR83","first-page":"948","volume":"100","author":"H Heger","year":"1980","unstructured":"Heger H, Hjort PF, Evensen SA. Health costs analysis of hemophilia in Norway. Tidsskr den Nor laegeforening Tidsskr Prakt Med ny Raekke. 1980;100(14):948\u201353.","journal-title":"Tidsskr den Nor laegeforening Tidsskr Prakt Med ny Raekke"},{"issue":"1","key":"540_CR84","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12962-023-00436-w","volume":"21","author":"HC Turner","year":"2023","unstructured":"Turner HC, et al. What are economic costs and when should they be used in health economic studies? Cost Eff Resour Alloc. 2023;21(1):31. https:\/\/doi.org\/10.1186\/s12962-023-00436-w.","journal-title":"Cost Eff Resour Alloc"},{"issue":"10","key":"540_CR85","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40273-020-00942-2","volume":"38","author":"DD Kim","year":"2020","unstructured":"Kim DD, Silver MC, Kunst N, Cohen JT, Ollendorf DA, Neumann PJ. Perspective and costing in cost-effectiveness analysis, 1974\u20132018. Pharmacoeconomics. 2020;38(10):1135\u201345. https:\/\/doi.org\/10.1007\/s40273-020-00942-2.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"540_CR86","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.7507\/1672-2531.202208070","volume":"22","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang Y, Luo M, Chen P, Ma A. Pharmacoeconomic studies on coagulation factor VIII for the treatment of hemophilia A: a systematic review. Chin J Evid Based Med. 2022;22(12):1419\u201327. https:\/\/doi.org\/10.7507\/1672-2531.202208070.","journal-title":"Chin J Evid Based Med"},{"issue":"5","key":"540_CR87","first-page":"e301","volume":"24","author":"J O\u2019Hara","year":"2018","unstructured":"O\u2019Hara J, Sima CS, Frimpter J, Paliargues F, Chu P, Presch I. Long-term outcomes from prophylactic or episodic treatment of haemophilia A: a systematic review. Haemophilia. 2018;24(5):e301\u201311.","journal-title":"Haemophilia"},{"issue":"1\u20132","key":"540_CR88","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.hjdsi.2016.04.004","volume":"5","author":"JM Polinski","year":"2017","unstructured":"Polinski JM, Kowal MK, Gagnon M, Brennan TA, Shrank WH. Home infusion: safe, clinically effective, patient preferred, and cost saving. Healthc (Amsterdam, Netherlands). 2017;5(1\u20132):68\u201380. https:\/\/doi.org\/10.1016\/j.hjdsi.2016.04.004.","journal-title":"Healthc (Amsterdam, Netherlands)"},{"issue":"2","key":"540_CR89","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1017\/s0266462300006930","volume":"11","author":"D Ross-Degnan","year":"1995","unstructured":"Ross-Degnan D, Soumerai SB, Avorn J, Bohn RL, Bright R, Aledort LM. Hemophilia home treatment. Economic analysis and implications for health policy. Int J Technol Assess Health Care. 1995;11(2):327\u201344. https:\/\/doi.org\/10.1017\/s0266462300006930.","journal-title":"Int J Technol Assess Health Care"},{"issue":"3","key":"540_CR90","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1365-2516.2009.02179.x","volume":"16","author":"K Kavakli","year":"2010","unstructured":"Kavakli K, et al. The value of early treatment in patients with haemophilia and inhibitors. Haemophilia. 2010;16(3):487\u201394. https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02179.x.","journal-title":"Haemophilia"},{"issue":"4","key":"540_CR91","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12488","volume":"5","author":"EC van Balen","year":"2021","unstructured":"van Balen EC, et al. Patient-relevant health outcomes for hemophilia care: development of an international standard outcomes set. Res Pract Thromb Haemost. 2021;5(4): e12488. https:\/\/doi.org\/10.1002\/rth2.12488.","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"540_CR92","first-page":"306","volume":"125","author":"P Serban","year":"2021","unstructured":"Serban P, et al. Surgical comorbidities\u2014a high medical and financial burden for hemophilia care. Med Surg J. 2021;125(2):306\u201314.","journal-title":"Med Surg J"},{"issue":"1","key":"540_CR93","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17474086.2022.2030218","volume":"15","author":"EC Rodriguez-Merchan","year":"2022","unstructured":"Rodriguez-Merchan EC, De la Corte-Rodriguez H, Alvarez-Roman T, Gomez-Cardero P, Encinas-Ullan CA, Jimenez-Yuste V. Total knee arthroplasty in hemophilia: lessons learned and projections of what\u2019s next for hemophilic knee joint health. Expert Rev Hematol. 2022;15(1):65\u201382. https:\/\/doi.org\/10.1080\/17474086.2022.2030218.","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"540_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00132-0","volume":"8","author":"A Srivastava","year":"2021","unstructured":"Srivastava A. The case for equitable haemophilia care. Lancet Haematol. 2021;8(9): e626.","journal-title":"Lancet Haematol."},{"issue":"1","key":"540_CR95","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13023-019-1175-5","volume":"14","author":"A Caf\u00e9","year":"2019","unstructured":"Caf\u00e9 A, et al. Haemophilia A: health and economic burden of a rare disease in Portugal. Orphanet J Rare Dis. 2019;14(1):211. https:\/\/doi.org\/10.1186\/s13023-019-1175-5.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"540_CR96","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-47. https:\/\/doi.org\/10.1111\/j.1365-2516.2012.02909.x.","journal-title":"Haemophilia"},{"issue":"6","key":"540_CR97","first-page":"445","volume":"7","author":"JGJ Mosqueda","year":"2002","unstructured":"Mosqueda JGJ, Omnes L-F, Chicoye A, Durand-Zaleski I. Medico-economic assessment of haemophilia A at the dawn of the new millennium. H\u00e9matologie. 2002;7(6):445\u201352.","journal-title":"H\u00e9matologie"},{"issue":"2","key":"540_CR98","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2516.2008.01969.x","volume":"15","author":"C Knight","year":"2009","unstructured":"Knight C, Dan\u00f8 AM, Kennedy-Martin T. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor\/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia. 2009;15(2):405\u201319. https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01969.x.","journal-title":"Haemophilia"},{"issue":"1","key":"540_CR99","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1111\/j.1365-2516.2009.02100.x","volume":"16","author":"MND Di Minno","year":"2010","unstructured":"Di Minno MND, Di Minno G, Di Capua M, Cerbone AM, Coppola A. Cost of care of haemophilia with inhibitors. Haemophilia. 2010;16(1):e190\u2013201.","journal-title":"Haemophilia"},{"issue":"4","key":"540_CR100","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3111\/13696998.2011.595462","volume":"14","author":"JW Hay","year":"2011","unstructured":"Hay JW, Zhou Z-Y. Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa. J Med Econ. 2011;14(4):516\u201325.","journal-title":"J Med Econ"},{"issue":"2","key":"540_CR101","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1586\/14737167.2015.1001372","volume":"15","author":"SD Grosse","year":"2015","unstructured":"Grosse SD, Chaugule SS, Hay JW. Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Rev Pharmacoecon Outcomes Res. 2015;15(2):267\u201383. https:\/\/doi.org\/10.1586\/14737167.2015.1001372.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"Suppl 3","key":"540_CR102","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/hae.13000","volume":"22","author":"CHT Yeung","year":"2016","unstructured":"Yeung CHT, et al. Care models in the management of haemophilia: a systematic review. Haemophilia. 2016;22(Suppl 3):31\u201340. https:\/\/doi.org\/10.1111\/hae.13000.","journal-title":"Haemophilia"},{"issue":"2","key":"540_CR103","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1111\/hae.13173","volume":"23","author":"M Drummond","year":"2017","unstructured":"Drummond M, Houwing N, Slothuus U, Giangrande P. Making economic evaluations more helpful for treatment choices in haemophilia. Haemophilia. 2017;23(2):e58\u201366. https:\/\/doi.org\/10.1111\/hae.13173.","journal-title":"Haemophilia"},{"issue":"5","key":"540_CR104","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/hae.13777","volume":"25","author":"F Peyvandi","year":"2019","unstructured":"Peyvandi F, et al. Burden of mild haemophilia A: systematic literature review. Haemophilia. 2019;25(5):755\u201363. https:\/\/doi.org\/10.1111\/hae.13777.","journal-title":"Haemophilia"},{"issue":"3","key":"540_CR105","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/17474086.2020.1716726","volume":"13","author":"EC Rodriguez-Merchan","year":"2020","unstructured":"Rodriguez-Merchan EC. The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality. Expert Rev Hematol. 2020;13(3):269\u201374. https:\/\/doi.org\/10.1080\/17474086.2020.1716726.","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"540_CR106","doi-asserted-by":"publisher","first-page":"576","DOI":"10.18553\/jmcp.2023.29.5.576","volume":"29","author":"JA Tice","year":"2023","unstructured":"Tice JA, et al. The effectiveness and value of gene therapy for hemophilia: a summary from the Institute for Clinical and Economic Review\u2019s California Technology Assessment Forum. J Manag Care Spec Pharm. 2023;29(5):576\u201381. https:\/\/doi.org\/10.18553\/jmcp.2023.29.5.576.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"540_CR107","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jval.2020.10.014","volume":"24","author":"I Aranda-Reneo","year":"2021","unstructured":"Aranda-Reneo I, Rodr\u00edguez-S\u00e1nchez B, Pe\u00f1a-Longobardo LM, Oliva-Moreno J, L\u00f3pez-Bastida J. Can the consideration of societal costs change the recommendation of economic evaluations in the field of rare diseases? An empirical analysis. Value Heal. 2021;24(3):431\u201342. https:\/\/doi.org\/10.1016\/j.jval.2020.10.014.","journal-title":"Value Heal."},{"issue":"Suppl 1","key":"540_CR108","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10198-019-01066-x","volume":"20","author":"V Brodszky","year":"2019","unstructured":"Brodszky V, et al. Cost-of-illness studies in nine Central and Eastern European countries. Eur J Heal Econ HEPAC Heal Econ Prev Care. 2019;20(Suppl 1):155\u201372. https:\/\/doi.org\/10.1007\/s10198-019-01066-x.","journal-title":"Eur J Heal Econ HEPAC Heal Econ Prev Care"},{"key":"540_CR109","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1016\/j.jval.2022.09.540","volume":"25","author":"AO de Labry-Lima","year":"2022","unstructured":"de Labry-Lima AO, Ponce-Polo A, Garc\u00eda-Moch\u00f3n L, Ortega-Ortega M, P\u00e9rez-Troncoso D, Epstein D. Challenges for economic evaluations of advanced therapy medicinal products: a systematic review. Value Heal. 2022;25:S111.","journal-title":"Value Heal."},{"key":"540_CR110","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01051-4","author":"JK Ho","year":"2021","unstructured":"Ho JK, et al. Economic evidence on potentially curative gene therapy products: a systematic literature review. Pharmoeconomics. 2021. https:\/\/doi.org\/10.1007\/s40273-021-01051-4.","journal-title":"Pharmoeconomics."},{"issue":"6","key":"540_CR111","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1111\/bcp.14275","volume":"87","author":"H Lloyd-Williams","year":"2021","unstructured":"Lloyd-Williams H, Hughes DA. A systematic review of economic evaluations of advanced therapy medicinal products. Br J Clin Pharmacol. 2021;87(6):2428\u201343.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"540_CR112","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/joim.12434","volume":"279","author":"M Osooli","year":"2016","unstructured":"Osooli M, Berntorp E. Registry-based outcome assessment in haemophilia: a scoping study to explore the available evidence. J Intern Med. 2016;279(6):502\u201314. https:\/\/doi.org\/10.1111\/joim.12434.","journal-title":"J Intern Med"},{"issue":"6","key":"540_CR113","doi-asserted-by":"publisher","first-page":"647","DOI":"10.18553\/jmcp.2023.29.6.647","volume":"29","author":"Y Chen","year":"2023","unstructured":"Chen Y, Cheng SJ, Thornhill T, Solari P, Sullivan SD. Health care costs and resource use of managing hemophilia A: a targeted literature review. J Manag Care Spec Pharm. 2023;29(6):647\u201358. https:\/\/doi.org\/10.18553\/jmcp.2023.29.6.647.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"540_CR114","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1365-2516.2007.01562.x","volume":"14","author":"A Nicholson","year":"2008","unstructured":"Nicholson A, et al. Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of the International Prophylaxis Study Group. Haemophilia. 2008;14(1):127\u201332. https:\/\/doi.org\/10.1111\/j.1365-2516.2007.01562.x.","journal-title":"Haemophilia"},{"issue":"3","key":"540_CR115","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/hae.14794","volume":"29","author":"K Batt","year":"2023","unstructured":"Batt K, et al. Real-world analysis of patients with haemophilia A and haemophilia A carriers in the United States: demographics, clinical characteristics and costs. Haemophilia. 2023;29(3):809\u201318. https:\/\/doi.org\/10.1111\/hae.14794.","journal-title":"Haemophilia"},{"issue":"4","key":"540_CR116","first-page":"449","volume":"28","author":"CD Thornburg","year":"2022","unstructured":"Thornburg CD, et al. Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States. J Manag Care Spec Pharm. 2022;28(4):449\u201360.","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"540_CR117","doi-asserted-by":"publisher","first-page":"e12825","DOI":"10.1002\/rth2.12825","volume":"6","author":"A Nagao","year":"2022","unstructured":"Nagao A, et al. Burden of congenital hemophilia A requiring treatment in Japan: the HIKOBOSHI study. Res Pract Thromb Haemost. 2022;6(7):e12825. https:\/\/doi.org\/10.1002\/rth2.12825.","journal-title":"Res Pract Thromb Haemost"},{"key":"540_CR118","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2049552","author":"T Burke","year":"2022","unstructured":"Burke T, et al. Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B. J Med Econ. 2022. https:\/\/doi.org\/10.1080\/13696998.2022.2049552.","journal-title":"J Med Econ"},{"issue":"6","key":"540_CR119","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/17474086.2023.2198207","volume":"16","author":"M Escobar","year":"2023","unstructured":"Escobar M, et al. A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors. Expert Rev Hematol. 2023;16(6):467\u201374.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"540_CR120","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41687-022-00413-6","volume":"6","author":"SM Szabo","year":"2022","unstructured":"Szabo SM, Audhya IF, Feeny D, Neumann P, Malone DC, Gooch KL. Societal perspectives on disease and treatment attributes characterizing rare diseases: a qualitative study from the United States. J Patient-Report Outcomes. 2022;6(1):9. https:\/\/doi.org\/10.1186\/s41687-022-00413-6.","journal-title":"J Patient-Report Outcomes"},{"issue":"4","key":"540_CR121","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40273-021-01017-6","volume":"39","author":"RB McQueen","year":"2021","unstructured":"McQueen RB, Slejko JF. Toward modified impact inventory tables to facilitate patient-centered value assessment. Pharmacoeconomics. 2021;39(4):379\u201382. https:\/\/doi.org\/10.1007\/s40273-021-01017-6.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"540_CR122","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/hae.13862","volume":"26","author":"MW Skinner","year":"2020","unstructured":"Skinner MW, et al. Achieving the unimaginable: health equity in haemophilia. Haemophilia. 2020;26(1):17\u201324.","journal-title":"Haemophilia"},{"issue":"6","key":"540_CR123","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.3390\/ijerph20064732","volume":"20","author":"T Adachi","year":"2023","unstructured":"Adachi T, et al. Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges. Int J Environ Res Public Health. 2023;20(6):4732.","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"540_CR124","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cnre.2017.10.004","volume":"4","author":"H Zhao","year":"2017","unstructured":"Zhao H, Zhao P, Wang Y-N, Guo Y-L, Wu R-H. Reasons for failure to continue home therapy in patients with hemophilia: a qualitative study. Chin Nurs Res. 2017;4(4):178\u201381. https:\/\/doi.org\/10.1016\/j.cnre.2017.10.004.","journal-title":"Chin Nurs Res"},{"issue":"8","key":"540_CR125","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1055\/s-0042-1756188","volume":"48","author":"M Franchini","year":"2022","unstructured":"Franchini M, Mannucci PM. The more recent history of hemophilia treatment. Semin Thromb Hemost. 2022;48(8):904\u201310. https:\/\/doi.org\/10.1055\/s-0042-1756188.","journal-title":"Semin Thromb Hemost"},{"key":"540_CR126","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/hae.14531","volume":"28","author":"M Lewandowska","year":"2022","unstructured":"Lewandowska M, Nasr S, Shapiro AD. Therapeutic and technological advancements in haemophilia care: quantum leaps forward. Haemophilia. 2022;28:77\u201392.","journal-title":"Haemophilia"},{"issue":"3","key":"540_CR127","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12695","volume":"6","author":"MC Ozelo","year":"2022","unstructured":"Ozelo MC, Yamaguti-Hayakawa GG. Impact of novel hemophilia therapies around the world. Res Pract Thromb Haemost. 2022;6(3): e12695.","journal-title":"Res Pract Thromb Haemost."},{"key":"540_CR128","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2147\/JBM.S371438","volume":"13","author":"NS Bolous","year":"2022","unstructured":"Bolous NS, Bhatt N, Bhakta N, Neufeld EJ, Davidoff AM, Reiss UM. Gene therapy and hemophilia: where do we go from here? J Blood Med. 2022;13:559\u201380.","journal-title":"J Blood Med."},{"key":"540_CR129","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2516.2005.01153.x","volume":"11","author":"C Knight","year":"2005","unstructured":"Knight C. Health economics of treating haemophilia A with inhibitors. Haemophilia. 2005;11:11\u20137.","journal-title":"Haemophilia"},{"issue":"8","key":"540_CR130","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/14712598.2019.1614163","volume":"19","author":"G Castaman","year":"2019","unstructured":"Castaman G, Linari S. Current and emerging biologics for the treatment of hemophilia. Expert Opin Biol Ther. 2019;19(8):801\u201310.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"540_CR131","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bjh.18379","volume":"200","author":"K Nogami","year":"2023","unstructured":"Nogami K, Shima M. Current and future therapies for haemophilia\u2014beyond factor replacement therapies. Br J Haematol. 2023;200(1):23\u201334.","journal-title":"Br J Haematol"},{"issue":"11","key":"540_CR132","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1111\/bcp.14838","volume":"87","author":"F Tomeo","year":"2021","unstructured":"Tomeo F, Mariz S, Brunetta AL, Stoyanova-Beninska V, Penttila K, Magrelli A. Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective. Br J Clin Pharmacol. 2021;87(11):4183\u201396.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"540_CR133","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","volume":"133","author":"AC Weyand","year":"2019","unstructured":"Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019;133(5):389\u201398. https:\/\/doi.org\/10.1182\/blood-2018-08-872291.","journal-title":"Blood"},{"issue":"6","key":"540_CR134","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/jth.15705","volume":"20","author":"J Voorberg","year":"2022","unstructured":"Voorberg J, Postmus T, Schols S. Next generation FVIII mimetic bispecific antibody for hemophilia A. J Thromb Haemost. 2022;20(6):1301\u20135.","journal-title":"J Thromb Haemost"},{"key":"540_CR135","doi-asserted-by":"publisher","DOI":"10.1101\/2022.12.19.520692v3.full","author":"Y Teranishi-Ikawa","year":"2022","unstructured":"Teranishi-Ikawa Y, et al. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a non-hemophiliac state. bioRxiv. 2022. https:\/\/doi.org\/10.1101\/2022.12.19.520692v3.full.","journal-title":"bioRxiv"},{"issue":"21","key":"540_CR136","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","volume":"374","author":"M Shima","year":"2016","unstructured":"Shima M, et al. Factor VIII\u2013mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374(21):2044\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1511769.","journal-title":"N Engl J Med"},{"issue":"S4","key":"540_CR137","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/hae.14524","volume":"28","author":"J Mahlangu","year":"2022","unstructured":"Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. Haemophilia. 2022;28(S4):103\u201310. https:\/\/doi.org\/10.1111\/hae.14524.","journal-title":"Haemophilia"},{"key":"540_CR138","unstructured":"Carcao M, Goudemand J. Inhibitors in hemophilia: a primer, 5th ed. Montr\u00e9al: World Federation of Hemophilia, 2018. [Online]. https:\/\/www1.wfh.org\/publication\/files\/pdf-1122.pdf"},{"issue":"6","key":"540_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.102181","volume":"7","author":"P Persson","year":"2023","unstructured":"Persson P, Amstrup A-B, Coester HV, Matytsina I, Bas S. Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults. Res Pract Thromb Haemost. 2023;7(6): 102181. https:\/\/doi.org\/10.1016\/j.rpth.2023.102181.","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"540_CR140","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/jth.15682","volume":"20","author":"B Lauritzen","year":"2022","unstructured":"Lauritzen B, et al. A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: results from safety studies in cynomolgus monkeys. J Thromb Haemost. 2022;20(6):1312\u201324. https:\/\/doi.org\/10.1111\/jth.15682.","journal-title":"J Thromb Haemost"},{"issue":"Supplement 1","key":"540_CR141","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1182\/blood-2022-163554","volume":"140","author":"SV Seremetis","year":"2022","unstructured":"Seremetis SV, Clausen WHO, Matytsina I, Nissen SM, W\u00e5hlander K. Mim8 clinical development program: an overview of the frontier studies. Blood. 2022;140(Supplement 1):5630\u20131.","journal-title":"Blood"},{"issue":"11","key":"540_CR142","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40265-023-01912-6","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Concizumab: first approval. Drugs. 2023;83(11):1053\u20139. https:\/\/doi.org\/10.1007\/s40265-023-01912-6.","journal-title":"Drugs"},{"key":"540_CR143","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/JBM.S390521","volume":"14","author":"S Boyce","year":"2023","unstructured":"Boyce S, Rangarajan S. RNAi for the treatment of people with hemophilia: current evidence and patient selection. J Blood Med. 2023;14:317\u201327. https:\/\/doi.org\/10.2147\/JBM.S390521.","journal-title":"J Blood Med."},{"key":"540_CR144","unstructured":"Sanofi. Press release: two fitusiran phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia. Online. [Online]. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2023\/2023-04-04-05-00-00-2640246"},{"issue":"10386","key":"540_CR145","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/S0140-6736(23)00514-7","volume":"401","author":"F Peyvandi","year":"2023","unstructured":"Peyvandi F, Garagiola I, Abbattista M. Fitusiran in haemophilia: a breakthrough drug with many unknowns. Lancet. 2023;401(10386):1400\u20131.","journal-title":"Lancet"},{"key":"540_CR146","unstructured":"ClinicalTrials.gov. The efficacy and safety of SerpinPC in participants with severe hemophilia A or moderately severe to severe hemophilia B (PRESent-2),\u201d Online. [Online]. https:\/\/clinicaltrials.gov\/study\/NCT05789524"},{"issue":"3","key":"540_CR147","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1055\/s-0040-1716751","volume":"121","author":"K Aymonnier","year":"2021","unstructured":"Aymonnier K, Kawecki C, Arocas V, Boulaftali Y, Bouton MC. Serpins, new therapeutic targets for hemophilia. Thromb Haemost. 2021;121(3):261\u20139. https:\/\/doi.org\/10.1055\/s-0040-1716751.","journal-title":"Thromb Haemost"},{"key":"540_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.622778","author":"EP Bianchini","year":"2021","unstructured":"Bianchini EP, Auditeau C, Razanakolona M, Vasse M, Borgel D. Serpins in hemostasis as therapeutic targets for bleeding or thrombotic disorders. Front Cardiovasc Med. 2021. https:\/\/doi.org\/10.3389\/fcvm.2020.622778.","journal-title":"Front Cardiovasc Med"},{"key":"540_CR149","doi-asserted-by":"publisher","DOI":"10.3390\/ph15101183","author":"R Gualtierotti","year":"2022","unstructured":"Gualtierotti R, et al. Updates on novel non-replacement drugs for hemophilia. Pharmaceuticals. 2022. https:\/\/doi.org\/10.3390\/ph15101183.","journal-title":"Pharmaceuticals"},{"issue":"4","key":"540_CR150","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.ymthe.2019.11.006","volume":"28","author":"JSS Butterfield","year":"2020","unstructured":"Butterfield JSS, Hege KM, Herzog RW, Kaczmarek R. A molecular revolution in the treatment of hemophilia. Mol Ther. 2020;28(4):997\u20131015.","journal-title":"Mol Ther"},{"issue":"24","key":"540_CR151","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1177\/15353702221147565","volume":"247","author":"GG Yamaguti-Hayakawa","year":"2022","unstructured":"Yamaguti-Hayakawa GG, Ozelo MC. Gene therapy for hemophilia: looking beyond factor expression. Exp Biol Med (Maywood). 2022;247(24):2223\u201332. https:\/\/doi.org\/10.1177\/15353702221147565.","journal-title":"Exp Biol Med (Maywood)"},{"key":"540_CR152","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810228","author":"G Castaman","year":"2022","unstructured":"Castaman G, Di Minno G, De Cristofaro R, Peyvandi F. The arrival of gene therapy for patients with hemophilia A. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231810228.","journal-title":"Int J Mol Sci"},{"issue":"10274","key":"540_CR153","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","volume":"397","author":"ME Mancuso","year":"2021","unstructured":"Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021;397(10274):630\u201340.","journal-title":"Lancet"},{"issue":"1","key":"540_CR154","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/hae.13088","volume":"23","author":"K Fischer","year":"2017","unstructured":"Fischer K, et al. Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective. Haemophilia. 2017;23(1):11\u201324. https:\/\/doi.org\/10.1111\/hae.13088.","journal-title":"Haemophilia"},{"issue":"2","key":"540_CR155","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/rth2.12195","volume":"3","author":"BA Konkle","year":"2019","unstructured":"Konkle BA, Skinner M, Iorio A. Hemophilia trials in the twenty-first century: defining patient important outcomes. Res Pract Thromb Haemost. 2019;3(2):184\u201392. https:\/\/doi.org\/10.1002\/rth2.12195.","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"540_CR156","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/ejh.12881","volume":"99","author":"C Hermans","year":"2017","unstructured":"Hermans C, et al. Outcome measures for adult and pediatric hemophilia patients with inhibitors. Eur J Haematol. 2017;99(2):103\u201311. https:\/\/doi.org\/10.1111\/ejh.12881.","journal-title":"Eur J Haematol"},{"issue":"2","key":"540_CR157","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/hae.13085","volume":"23","author":"C Hermans","year":"2017","unstructured":"Hermans C, Klamroth R, Richards M, de Moerloose P, Garrido RP. Outcome measures in European patients with haemophilia: Survey of implementation in routine clinical practice, perception of relevance and recommendations by European treaters in the EHTSB. Haemophilia. 2017;23(2):222\u20139. https:\/\/doi.org\/10.1111\/hae.13085.","journal-title":"Haemophilia"},{"issue":"4","key":"540_CR158","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/rth2.12331","volume":"4","author":"S Dover","year":"2020","unstructured":"Dover S, Blanchette VS, Srivastava A, Fischer K, Abad A, Feldman BM. Clinical outcomes in hemophilia: towards development of a core set of standardized outcome measures for research. Res Pract Thromb Haemost. 2020;4(4):652\u20138. https:\/\/doi.org\/10.1002\/rth2.12331.","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"540_CR159","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2796.1994.tb00815.x","volume":"236","author":"LM Aledort","year":"1994","unstructured":"Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med. 1994;236(4):391\u20139. https:\/\/doi.org\/10.1111\/j.1365-2796.1994.tb00815.x.","journal-title":"J Intern Med"},{"issue":"4","key":"540_CR160","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00135.","journal-title":"Ann Intern Med"},{"issue":"1","key":"540_CR161","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262273","volume":"17","author":"CJ Delgado-Flores","year":"2022","unstructured":"Delgado-Flores CJ, Garc\u00eda-Gomero D, Salvador-Salvador S, Montes-Alvis J, Herrera-Cunti C, Taype-Rondan A. Effects of replacement therapies with clotting factors in patients with hemophilia: a systematic review and meta-analysis. PLoS ONE. 2022;17(1): e0262273.","journal-title":"PLoS ONE"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00540-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-024-00540-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00540-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T10:18:21Z","timestamp":1740565101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-024-00540-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":161,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["540"],"URL":"https:\/\/doi.org\/10.1007\/s41669-024-00540-4","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"10 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Due to a typesetting mistake, there were some misplaced commas after the first digits of the data in Fig. 3 and they have now been corrected.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AAE set the review design; conducted the systematic literature search; retrieved, screened, and reviewed potential sources of evidence; extracted and analysed data; synthesised results from the included studies; and wrote the manuscript.\u00a0NSB supervised; contributed to data extraction, data analysis, and synthesising results; and reviewed and wrote the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"NSB is partly funded by ALSAC. The funding source had no role in the design and conduct of the study; management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Charts and figures in this manuscript will be available under the journal policy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"All the information included in this manuscript will be available on the journal website.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The approval of the institutional review board (IRB) was not required for conducting this scoping review.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"AAE is an employee of Novo Nordisk Egypt. NSB does not have conflicts of interest for conducting this research project.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}